AHA 2019 | COMPLETE: Complete Revascularization Is Superior since It Treats Other Vulnerable Plaque

This COMPLETE sub-study using optical coherence tomography (OCT) showed the prevalence of vulnerable lesions other than the culprit which should provide a physiopathological explanation of the benefit of complete revascularization observed in the original study. 

highlights-aha2019-sub-complete

STEMI patients with multivessel disease will benefit from complete revascularization in terms of reduced cardiovascular death and repeat MI according to the COMPLETE study. This sub-study analyzed the sub-group of patients who had received OCT.

Nearly half of patients (47.3%) undergoing OCT during the second procedure after primary PCI showed a thin cap in non-culprit lesions. Non-culprit lesions with ≥70% stenosis diameter more often presented a thin cap. 


Read also: AHA 2019 | Treat Stroke to Target: Post-Stroke Aggressive Therapy with Statins.


This finding could explain the benefit of routine treatment of non-culprit lesions after primary PCI. However, the study is biased. Patients randomized to a conservative strategy after PCI, did not receive OCT and therefore were not checked for other vulnerable plaque. 

To definitely close the relation between multiple vulnerable plaque and events rate reduction with complete revascularization we should have also studied the COMPLETE conservative branch with OCT and find a similar rate of unstable lesions. 

With this study we can only extrapolate the idea and speculate with physiopathology.


Read also: AHA 2019 | Sapien vs Evolut: A Head-to-Head Study Seems Mandatory.


The COMPLETE study showed complete revascularization after successful primary PCI reduces the risk of cardiovascular death or repeat MI (HR 0.74; CI 95% 0.60-0.91) and cardiovascular death, repeat MI and ischemia driven revascularization (HR 0.51; CI 95% 0.43-0.61) vs. treating the culprit lesion alone.

This sub-study looked into plaque morphology by OCT of non-culprit lesions of patients randomized to complete revascularization (n=93).


Read also: AHA 2019 | TWILIGHT: Discontinue Aspirin after Acute Coronary Syndrome.


Angiographically more significant non-culprit lesions showed greater lipid burden by OCT, a thinner cap, more macrophage accumulation and more cholesterol crystals than non-obstructive lesions with thicker cap that often resulted more fibrous and calcified. 

Original Title: Non-culprit lesion plaque morphology in patients with ST-segment elevation myocardial infarction: results from the COMPLETE trial optical coherence tomography (OCT) substudy.

Reference: presentado por Pinilla-Echeverri N. en el congreso de la AHA 2019.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...